| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
|
| ln Vitro |
Compound 2 (LPA1 receptor antagonist 1) shows nearly little inhibitory action on LPA3, even at very high doses, while having extremely strong and highly specific inhibitory activity on LPA1. As far as we know, the most selective non-lipid LPA1 antagonist that has been documented thus far is LPA1 receptor antagonist 1. It seems that substances belonging to the N-aryltriazole chemical class (like LPA1 receptor antagonist 1) exhibit a significantly higher degree of LPA1 selectivity in comparison to substances belonging to the equivalent pyrazole group. Relative to Ki16425 and AM095; LPA1 receptor antagonist 1 had markedly enhanced antiproliferative effects. Attenuating LPA-induced NHLF proliferation and contraction is possible by the use of LPA1 receptor antagonist 1, which possesses the highest selectivity for LPA1.
|
|---|---|
| ln Vivo |
After intravenous LPA stimulation, mice given LPA1 receptor antagonist 1 orally experienced a dose-dependent decrease in serum histamine levels. LPA-induced histamine levels were dramatically inhibited in mice when LPA1 antagonist 1 (100 mg/kg, aqueous suspension) was given orally prior to an intravenous injection of LPA. An obvious PK/PD link between antagonist 1 and LPA-induced plasma histamine concentrations was shown by the correlation between LPA1 receptor levels. Analysis of plasma samples revealed that AM095 concentrations were more than 65-fold higher than LPA1 receptor antagonist 1 (100 mg/kg), despite the fact that AM095 virtually entirely blocks histamine release (100 mg/kg). Lower effective dosages for this class of drugs may be possible if pharmacokinetic characteristics are further improved, as evidenced by LPA1 receptor antagonist 1's capacity to inhibit histamine release at significantly lower plasma concentrations [1].
|
| References |
| Molecular Formula |
C28H26N4O4
|
|---|---|
| Molecular Weight |
482.530446529388
|
| Exact Mass |
482.195
|
| CAS # |
1396006-71-5
|
| PubChem CID |
71265339
|
| Appearance |
Typically exists as solid at room temperature
|
| LogP |
5.741
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
36
|
| Complexity |
768
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC(C1(C2C=CC(C3C=CC(=CC=3)N3C(=C(C)N=N3)NC(=O)O[C@H](C)C3C=CC=CC=3)=CC=2)CC1)=O
|
| InChi Key |
PXQUHYSYFWQRMF-LJQANCHMSA-N
|
| InChi Code |
InChI=1S/C28H26N4O4/c1-18-25(29-27(35)36-19(2)20-6-4-3-5-7-20)32(31-30-18)24-14-10-22(11-15-24)21-8-12-23(13-9-21)28(16-17-28)26(33)34/h3-15,19H,16-17H2,1-2H3,(H,29,35)(H,33,34)/t19-/m1/s1
|
| Chemical Name |
1-[4-[4-[4-methyl-5-[[(1R)-1-phenylethoxy]carbonylamino]triazol-1-yl]phenyl]phenyl]cyclopropane-1-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0724 mL | 10.3621 mL | 20.7241 mL | |
| 5 mM | 0.4145 mL | 2.0724 mL | 4.1448 mL | |
| 10 mM | 0.2072 mL | 1.0362 mL | 2.0724 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
